Lexicon Touts New Favorable Data On Sotaglifozin Cardio Data

  • At the American College of Cardiology, Lexicon Pharmaceuticals Inc LXRX highlighted a new data analysis from the SCORED Phase 3 trial of sotagliflozin in Type 2 diabetes and kidney disease patients.
  • Sotagliflozin significantly reduced major adverse cardiovascular events (MACE) of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke compared to placebo.
  • Also See: Lexicon Announces Loan Facility Of $150M With Oxford Finance To Support Sotagliflozin Commercialization.
  • A follow-up analysis of the trial revealed consistent reductions in major adverse cardiovascular events (MACE) in two subgroups —a 21% reduction in MACE in patients with cardiovascular disease and a 26% reduction in MACE in those without CVD.
  • In February, Lexicon pulled back a submission for approval in Type 2 diabetes patients with heart failure. That came on top of an FDA rejection for sotagliflozin in 2019 in Type 1 diabetes.
  • Price Action: LXRX shares are up 3.11% at $2.32 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!